14167-51-2

Usage

Uses

Used in Cancer Research:
(3a,16a)-3,16-dihydroxy-Androst-5-en-17-one is used as a target in cancer research due to its potential anti-estrogenic and anti-invasive properties. It may contribute to the development of novel therapeutic strategies for the treatment of various types of cancer.
Used in Hormonal Therapies:
In the field of hormonal therapies, (3a,16a)-3,16-dihydroxy-Androst-5-en-17-one is utilized for its role in the regulation of endocrine functions. It may help in the management of hormonal imbalances and related conditions.
Used as a Precursor in Pharmaceutical Industry:
(3a,16a)-3,16-dihydroxy-Androst-5-en-17-one is used as a precursor in the synthesis of other steroid hormones in the pharmaceutical industry. Its role in the biosynthesis of estrogens and androgens makes it a valuable component in the development of medications targeting hormonal-related health issues.

Upstream product

• 14456-20-3 3β-acetoxy-5-androsten-17-one-17-ethyleneketal 
• 2283-82-1 3α-hydroxy-androst-5-en-17-one 
• 853-23-6 prasterone acetate 
• 14456-21-4 17,17-ethylenedioxy-androst-5-ene-3α-ol 
• 14456-20-3 5-androsten-3α-ol-17-one acetate 17-ethylene ketal 
• 15577-68-1 17,17-ethylenedioxy-3β-methanesulfonyloxy-androstane-5α-ol 
• 13262-99-2 17,17-ethylenedioxy-androstane-3β,5α-diol 
• 115350-45-3 3β-acetoxy-5α,6α-epoxy-androst-17-one, ethylene ketal 
• 1016226-71-3 16α-bromo-5-androst-5-ene-17-one-3α-ol 

Relevant academic research and scientific papers

STEROID TETROL SOLID STATE FORMS-2

The invention relates to solid state forms of androst-5-ene-3α,7β,16α,17β- tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes.

Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols

Two natural 5-androstene steroid tetrols, androst-5-ene-3β,7β, 16α,17β-tetrol (HE3177) and androst-5-ene-3α,7β,16α, 17β-tetrol (HE3413), were discovered in human plasma and urine. These compounds had significant aqueous solubility, did not bind or transactivate steroid-binding nuclear hormone receptors, and were not immunosuppressive in murine mixed-lymphocyte studies. Both compounds appear to be metabolic end products, as they were resistant to primary and secondary metabolism. Both were orally bioavailable, and were very well tolerated in a two-week dose-intensive toxicity study in mice. Anti-inflammatory properties were found with exogenous administration of these compounds in rodent disease models of multiple sclerosis, lung injury, chronic prostatitis, and colitis.

DRUGS AND USES

The invention relates to methods to treat specified clinical disorders such as hyperglycemia, type 2 diabetes, arthritis and multiple sclerosis. The invention also provides methods to identify and characterize drugs, which are characterized in part by eliciting a variable biologic or therapeutic effect on a biomolecule at one time and relative normalization of the biomolecule at another time point. Compounds include 17α-ethynylandrost-5-ene-3β,7β, 17β-triol or androst-5-ene-3β,4β, 16α, 17β-tetrol, which can be used as reference standards to facilitate assessing and characterizing such candidate drugs.